Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. Twist Bioscience Corporation has a collaboration agreement with Pandion Therapeutics, Inc. to apply its antibody optimization platform for a targeting arm of a bispecific antibody. The company was founded in 2013 and is headquartered in San Francisco, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone800-719-0671
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$54.38 million
Profitability
Miscellaneous
Employees289
Next Earnings Date5/5/2020 (Estimated)
OptionableNot Optionable
Twist Bioscience (NASDAQ:TWST) Frequently Asked Questions
What is Twist Bioscience's stock symbol?
Twist Bioscience trades on the NASDAQ under the ticker symbol "TWST."
How were Twist Bioscience's earnings last quarter?
Twist Bioscience Corp (NASDAQ:TWST) released its quarterly earnings results on Thursday, February, 6th. The company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.83) by $0.17. The firm had revenue of $17.20 million for the quarter, compared to the consensus estimate of $16.06 million. Twist Bioscience had a negative return on equity of 86.44% and a negative net margin of 234.22%. The business's quarterly revenue was up 49.6% compared to the same quarter last year. View Twist Bioscience's Earnings History.
When is Twist Bioscience's next earnings date?
What guidance has Twist Bioscience issued on next quarter's earnings?
Twist Bioscience updated its FY 2020
After-Hours earnings guidance on Thursday, February, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $80-84 million, compared to the consensus revenue estimate of $82.52 million.
What price target have analysts set for TWST?
2 equities research analysts have issued twelve-month price objectives for Twist Bioscience's stock. Their forecasts range from $42.00 to $42.00. On average, they anticipate Twist Bioscience's share price to reach $42.00 in the next twelve months. This suggests a possible upside of 27.1% from the stock's current price. View Analyst Price Targets for Twist Bioscience.
What is the consensus analysts' recommendation for Twist Bioscience?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Twist Bioscience in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Twist Bioscience.
Has Twist Bioscience been receiving favorable news coverage?
News articles about TWST stock have trended very negative this week, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Twist Bioscience earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Twist Bioscience.
Are investors shorting Twist Bioscience?
Twist Bioscience saw a drop in short interest in the month of January. As of January 31st, there was short interest totalling 3,940,000 shares, a drop of 8.4% from the January 15th total of 4,300,000 shares. Based on an average trading volume of 311,000 shares, the days-to-cover ratio is currently 12.7 days. Currently, 20.7% of the company's shares are sold short. View Twist Bioscience's Current Options Chain.
Who are some of Twist Bioscience's key competitors?
Some companies that are related to Twist Bioscience include China Biologic Products (CBPO), bluebird bio (BLUE), Spark Therapeutics (ONCE), Adaptive Biotechnologies (ADPT), Ablynx (ABLYF), Momenta Pharmaceuticals (MNTA), Iovance Biotherapeutics (IOVA), Crispr Therapeutics (CRSP), Halozyme Therapeutics (HALO), Allogene Therapeutics (ALLO), Audentes Therapeutics (BOLD), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Alector (ALEC) and Regenxbio (RGNX).
What other stocks do shareholders of Twist Bioscience own?
Who are Twist Bioscience's key executives?
Twist Bioscience's management team includes the folowing people:
- Dr. Emily Marine Leproust, Co-Founder, Pres, CEO & Director (Age 45)
- Mr. James M. Thorburn, Chief Financial Officer (Age 64)
- Mr. Mark Daniels Esq., Sr. VP, Chief Legal Officer, Gen. Counsel, Chief Ethics & Compliance Officer and Sec. (Age 56)
- Mr. William Charles Banyai, COO & Director (Age 64)
- Mr. Bill Peck, Chief Technology Officer (Age 59)
When did Twist Bioscience IPO?
(TWST) raised $75 million in an initial public offering on Wednesday, October 31st 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Cowen acted as the underwriters for the IPO and Allen & Company and Baird were co-managers.
Who are Twist Bioscience's major shareholders?
Twist Bioscience's stock is owned by a variety of of retail and institutional investors. Top institutional investors include State Street Corp (2.67%), Capital World Investors (1.99%), Lord Abbett & CO. LLC (1.57%), FMR LLC (1.52%), Alyeska Investment Group L.P. (1.37%) and Massachusetts Financial Services Co. MA (1.36%). Company insiders that own Twist Bioscience stock include Bill Peck, James M Thorburn, Keith Crandell, Mark Daniels, Patrick John Finn, Patrick Weiss and William Banyai. View Institutional Ownership Trends for Twist Bioscience.
Which institutional investors are selling Twist Bioscience stock?
TWST stock was sold by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Barclays PLC, UBS Group AG, Windsor Creek Advisors LLC, FMR LLC, Rafferty Asset Management LLC and Citigroup Inc.. Company insiders that have sold Twist Bioscience company stock in the last year include Bill Peck, James M Thorburn, Mark Daniels, Patrick John Finn, Patrick Weiss and William Banyai. View Insider Buying and Selling for Twist Bioscience.
Which institutional investors are buying Twist Bioscience stock?
TWST stock was purchased by a variety of institutional investors in the last quarter, including Capital World Investors, Alyeska Investment Group L.P., ARK Investment Management LLC, Massachusetts Financial Services Co. MA, Lord Abbett & CO. LLC, Perceptive Advisors LLC, Perceptive Advisors LLC and Algert Global LLC. View Insider Buying and Selling for Twist Bioscience.
How do I buy shares of Twist Bioscience?
Shares of TWST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Twist Bioscience's stock price today?
One share of TWST stock can currently be purchased for approximately $33.05.
How big of a company is Twist Bioscience?
Twist Bioscience has a market capitalization of $1.17 billion and generates $54.38 million in revenue each year. The company earns $-107,670,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis. Twist Bioscience employs 289 workers across the globe.View Additional Information About Twist Bioscience.
What is Twist Bioscience's official website?
How can I contact Twist Bioscience?
Twist Bioscience's mailing address is 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 800-719-0671 or via email at [email protected]
MarketBeat Community Rating for Twist Bioscience (NASDAQ TWST)
MarketBeat's community ratings are surveys of what our community members think about Twist Bioscience and other stocks. Vote "Outperform" if you believe TWST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TWST will underperform the S&P 500 over the long term. You may vote once every thirty days.
